POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (4.20.2021, 10:36am CEST, WHO):   U.S. 38,084    India 259,170    Brazil 42,980    France 29,344    Russia 8,589    The United Kingdom 1,882    Turkey 55,802    Italy 12,688    Poland 7,302    Argentina 16,267    Columbia 16,871    Iran 24,346    Ukraine 6,506    Peru 7,131    Indonesia 4,952    Czechia 2,364    South Africa 1,089    The Netherlands 8,600    Chile 6,622    Canada 7,591    Romania 2,265    Iraq 7,775    Philippines 9,628    Pakistan 5,152    Hungary 2,680    Bangladesh 4,271    Jordan 3,509    Serbia 2,069    Austria 2,159    Japan 3,265    United Arab Emirates 1,803    Malaysia 2,078    Belarus 1,300    Greece 1,829    Azerbaijan 2,144    Tunisia 1,571    Nepal 1,227    Kuwait 1,510    Paraguay 1,801    Ethiopia 1,792    Venezuela 1,287    Oman 1,399    Bahrain 1,008    Uruguay 2,344    Puerto Rico 1,348    Cuba 1,060    Thailand 1,443    China 25    Singapore 20    New Zealand 1    Australia 24    South Korea 549   

DNA Mapping may lead to personalized cancer treatment

Staff Writer |
DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests.

Article continues below






By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis.

The study authors said their findings add to growing evidence that noninvasive, blood-based biopsies may help detect cancer earlier by tracking its evolution. They said this test may also significantly change how the disease is treated.

"Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said study co-senior author Dr. Ash Alizadeh, an assistant professor of medicine/oncology.

"We've moved beyond just measuring disease burden based on the amount of tumor DNA in the blood," Alizadeh said in a university news release.

The study included 92 people. They all had a common form of non-Hodgkin lymphoma known as diffuse large B-cell lymphoma. The disease is biologically diverse. That means patients with this disease tend to respond very differently to treatments, the researchers explained.

Roughly one-third of those with the disease relapse, or develop treatment resistant tumors, the researchers said. The researchers also said that some people with mild, slowly progressing forms of the disease may suddenly develop aggressive cancer.

Using an advanced DNA sequencing technique, the research team pinpointed circulating tumor DNA in samples of the patients' blood. They compared these results with previous blood samples that were taken from the patients, as well as blood samples of tumor cells from invasive biopsies.

"This transformation is very difficult to detect, and usually requires an invasive biopsy to diagnose," said study co-senior author Dr. Maximilian Diehn. He's an assistant professor of radiation oncology at Stanford.

"Our approach will allow us to monitor patients over time with a simple blood test, and may help us identify transformation much earlier," Diehn said.


What to read next

Drug trio shows major promise against myeloma
Doctors in South Korea successfully detect cancer cells in blood
Brain cancer treatment shows promise in early trial